Home / Indicators / Innovative drug out-licensing deal value vs Clinical trial country use share in China Innovative drug out-licensing deal value vs Clinical trial country use share in China Innovative drug out-licensing deal value and Clinical trial country use share in China, compared over time.
Change the pair
Compare different indicators
The series
Over time China, spaced by time
. Different units, drawn on separate scales and clipped to the years both
series publish — earlier history stays on each indicator's own page.
Read the values, not the heights.
Innovative drug out-licensing deal value
Unit: billion USD · 2 observations
Line chart Innovative drug out-licensing deal value Innovative drug out-licensing deal value. 2 observations from 2024 to 2025, ranging from 51.9 billion USD to 130 billion USD. Latest value 130 billion USD (2025).
billion USD
0
30
60
90
120
150
2019
2020
2021
2022
2023
2024
2025
51.9
130
Innovative drug out-licensing deal value Innovative drug out-licensing deal value. 2 observations from 2024 to 2025, ranging from 51.9 billion USD to 130 billion USD. Latest value 130 billion USD (2025).
billion USD
0
50
100
150
2019
2020
2021
2022
2023
2024
2025
51.9
130
Innovative drug out-licensing deal value Innovative drug out-licensing deal value. 2 observations from 2024 to 2025, ranging from 51.9 billion USD to 130 billion USD. Latest value 130 billion USD (2025).
billion USD
0
50
100
150
2019
2020
2021
2022
2023
2024
2025
51.9
130
View the underlying data Clinical trial country use share
Unit: % · 3 observations
Line chart Clinical trial country use share Clinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023).
%
0
3
6
9
12
15
2019
2020
2021
2022
2023
2024
2025
10%
15%
Clinical trial country use share Clinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023).
%
0
5
10
15
2019
2020
2021
2022
2023
2024
2025
10%
15%
Clinical trial country use share Clinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023).
%
0
5
10
15
2019
2020
2021
2022
2023
2024
2025
10%
15%
View the underlying data Provenance
Where these numbers come from Total monetary value of out-licensing agreements signed for innovative pharmaceutical products.
2 observations in China · source
organisations: NHSA
Percentage of total clinical trial country uses accounted for by a given region.
3 observations in China · source
organisations: IQVIA
Data published under CC BY 4.0 .
Series A as JSON · Series B as JSON